Pacira Pharmaceuticals Inc (PCRX) Releases Earnings Results, Beats Expectations By $0.16 EPS

Pacira Pharmaceuticals Inc (PCRX) reported quarterly earnings results on Thursday, Aug-4-2016. The company said it had a profit of $0.21 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.16. Analysts had a consensus of $0.05. The company posted revenue of $69.60 million in the period, compared to analysts expectations of $66.92 million. The company’s revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.20 EPS.

Many Wall Street Analysts have commented on Pacira Pharmaceuticals Inc. Pacira Pharmaceuticals Inc was Downgraded by Brean Capital to ” Hold” on Jul 1, 2016. Shares were Reiterated by Wedbush on May 25, 2016 to “Outperform” and Lowered the Price Target to $ 105 from a previous price target of $113 .

Pacira Pharmaceuticals Inc opened for trading at $37.78 and hit $38.51 on the upside on Tusday, eventually ending the session at $38.08, with a gain of 1.33% or 0.5 points. The heightened volatility saw the trading volume jump to 6,40,249 shares. Company has a market cap of $1,415 M.

In a different news, on Jun 8, 2016, Lauren Bullaro Riker (Vice President, Finance) sold 938 shares at $47.67 per share price. According to the SEC, on Jun 8, 2016, Laura Brege (director) sold 1,000 shares at $46.95 per share price. On Jun 8, 2016, Kristen Marie Williams (CAO and General Counsel) sold 600 shares at $47.20 per share price, according to the Form-4 filing with the securities and exchange commission.

Pacira Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the development commercialization and manufacture of pharmaceutical products based on its DepoFoam drug delivery technology primarily for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. DepoFoam is basis for the company’s lead product candidate EXPAREL a liposome injection of bupivacaine an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL DepoFoam is also the basis for its other commercial product DepoCyt(e) which the Company manufactures for its commercial partners as well as its other product candidates. The Company’s other product candidates include DepoMeloxicam and DepoTranexamic Acid.

Pacira Pharmaceuticals Inc

Leave a Reply

Pacira Pharmaceuticals Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pacira Pharmaceuticals Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.